<DOC>
	<DOCNO>NCT01004380</DOCNO>
	<brief_summary>The purpose study evaluate whether combination therapy farletuzumab ( MORAb-003 ) , carboplatin , pegylated liposomal doxorubicin ( PLD ) safe .</brief_summary>
	<brief_title>Safety Study Farletuzumab , Carboplatin Pegylated Liposomal Doxorubicin ( PLD ) Treat Platinum-sensitive Ovarian Cancer</brief_title>
	<detailed_description>Farletuzumab ( MORAb-003 ) monoclonal antibody potential effective agent epithelial ovarian cancer ( include primary fallopian tube peritoneal adenocarcinoma ) combination drug . Farletuzumab work different mechanism cancer therapeutic show well tolerate . This study allow opportunity determine combination therapy farletuzumab , carboplatin , PLD 1. safe , 2. assess potential drug-drug interaction , 3. prolong response chemotherapy .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Diagnosis epithelial ovarian cancer Must measurable disease CT MRI scan Must relapse define CA125 radiologically within 6 month completion first secondline platinum chemotherapy Must treat surgery candidate repeat carboplatin therapy Must normal cardiac ejection fraction baseline Subjects never respond first secondline platinumbased chemotherapy whose relapse occur &lt; 6 month last platinum therapy Subjects receive therapy treat ovarian cancer since last relapse Known central nervous system tumor involvement Evidence active invasive malignancy Clinically significant heart disease Known allergic reaction prior monoclonal antibody therapy document HAHA Previous treatment MORAb 003 ( farletuzumab ) Previous treatment anthracyclines Clinical contraindication use PLD</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Epithelial Ovarian Cancer</keyword>
	<keyword>Ovarian Cancer</keyword>
</DOC>